<DOC>
	<DOCNO>NCT00003594</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know regimen combination chemotherapy effective treating advance colorectal cancer . PURPOSE : Randomized phase III trial compare effectiveness various combination chemotherapy regimens treat patient advance , recurrent , metastatic colorectal cancer treat surgery radiation therapy .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare time progression patient locally advance , locally recurrent , metastatic colorectal adenocarcinoma treat combination oxaliplatin , fluorouracil , leucovorin calcium , irinotecan . - Compare quality life , response rate , time treatment failure , overall survival patient treat regimen . - Compare toxicity regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord ECOG performance status ( 0-1 v 2 ) , prior adjuvant chemotherapy ( yes v ) , prior immunotherapy ( yes v ) , age ( 65 vs 65 ) . Patients randomize one three treatment arm . Only arm II remain open accrual . - Arm I ( Saltz regimen ) : Patients receive irinotecan IV 90 minute follow leucovorin calcium IV 15 minute fluorouracil IV week 4 week follow 2 week rest . Courses repeat every 6 week . ( Arm I close accrual March 15 , 2002 . ) - Arm II ( FOLFOX4 regimen ) : Patients receive oxaliplatin IV 2 hour day 1 leucovorin calcium IV 2 hour plus fluorouracil IV 22 hour day 1 2 . Courses repeat every 2 week . - Arm III ( oxaliplatin plus irinotecan ) : Patients receive oxaliplatin IV 2 hour irinotecan IV 30 minute day 1 . Courses repeat every 3 week . ( Arm III close accrual March 15 , 2002 . ) Treatment continue absence disease progression unacceptable toxicity . Quality life assess treatment , treatment ( arm specific ) , completion treatment . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 825 patient ( 275 per arm ) accrue study thus far . Additional patient accrue arm II . ( Arms I III closed accrual March 15 , 2002 . )</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advance , locally recurrent , metastatic colorectal adenocarcinoma curable surgery radiotherapy Histological cytological requirement waive patient develop radiological clinical evidence metastatic cancer prior surgical resection unless : More 5 year elapse since primary surgery OR Primary cancer stage I II Site primary lesion must confirm endoscopically , radiologically , surgically large bowel Measurable evaluable disease No CNS metastases carcinomatous meningitis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL ( transfusion allow ) Hepatic : Bilirubin great 1.5 mg/dL AST great 5 time upper limit normal ( ULN ) Alkaline phosphatase great 5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No uncontrolled hypertension No unstable angina No symptomatic congestive heart failure No myocardial infarction within past 6 month No serious uncontrolled arrhythmia No New York Heart Association class III IV cardiac disease Pulmonary : No interstitial pneumonia extensive symptomatic interstitial fibrosis lung No pleural effusion ascites cause respiratory compromise ( grade 2 bad dyspnea ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active uncontrolled infection No symptomatic sensory peripheral neuropathy No known allergy platinum compound No history gastrointestinal bleeding unless determine acceptable enrol physician No prior concurrent malignancy within past 3 year except nonmelanoma skin cancer , carcinoma situ uterine cervix , resect malignant tumor le 10 % probability tumor relapse within 3 year diagnosis No medical psychiatric condition would preclude study No colonic small bowel disorder uncontrolled symptom 3 loose stool per day Colostomy ileostomy allow investigator 's discretion PRIOR CONCURRENT THERAPY : Biologic therapy : Prior adjuvant immunotherapy resect stage IIIV disease allow adjuvant therapy conclude least 1 year documentation recurrent disease No concurrent sargramostim ( GMCSF ) Chemotherapy : No prior chemotherapy advance colorectal cancer No prior standard adjuvant chemotherapy rectal cancer Prior adjuvant fluorouracil resect stage IIIV disease allow adjuvant therapy conclude least 1 year documentation recurrent disease Radiotherapy : See Disease Characteristics At least 4 week since prior major radiotherapy ( e.g. , chest bone palliative radiotherapy ) No prior radiotherapy 15 % bone marrow No prior standard adjuvant radiotherapy rectal cancer Surgery : See Disease Characteristics At least 4 week since prior major surgery ( e.g. , laparotomy ) ( 2 week minor surgery ) recover Insertion vascular access device consider major minor surgery Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>